CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB), a biotechnology company developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders, announced that it has retained intellectual property law firm Fish & Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, titled “Halogenated psilocybin derivatives and methods of using.”
The ’276 patent includes claims that appear relevant to Bretisilocin (GM-2505), a molecule currently in clinical trials that AbbVie agreed to acquire from Gilgamesh Pharmaceuticals on August 25, 2025, in a transaction valued at up to $1.2 billion. The PGR petition challenges claims within the ’276 patent that may relate to Bretisilocin and other protected compounds.
The ’276 patent family also includes one additional issued U.S. patent, a pending U.S. application, and related international applications filed in Australia, Canada, China, Europe, Japan, Mexico, and South Korea. This patent family is separate from those covering Enveric’s proprietary therapeutic pipeline, including its lead product candidate EB-003.
EB-003, a novel compound with dual agonism at 5-HT1B and 5-HT2A receptors, is being developed for depression and anxiety and is advancing toward an Investigational New Drug (IND) application for human clinical trials. Enveric’s broader pipeline also includes the EVM-401 series of small molecules and three out-licensed programs with potential aggregate milestone payments of up to $205 million, plus royalties on future sales.
“Enveric has built a diversified product pipeline and a broad intellectual property estate designed to deliver novel solutions for serious neuropsychiatric conditions,” said Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences. “As major pharmaceutical companies pursue novel approaches in this field, Enveric has gained attention and is well positioned with differentiated patented molecules, national and international patent portfolios, and multiple programs advancing toward clinical development directly and through licensees. Enveric will vigorously defend its intellectual property and take all steps necessary to maximize the value of its intellectual property for shareholders.”
Enveric’s intellectual property portfolio currently includes 26 issued U.S. patents and 60 pending national and international applications spanning five programs.
